The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

Inclusion criteria include: * be \>= 50 years of age or older (for the Zostavax® sub-study only) * be \>= 18 years of age or older (for the Shingrix® sub-study only) * be currently treated with abatacept therapy at the time of enrollment * Eligible women must be post-menopausal (\> 1 year since last menstrual period) or have a surgical history of bilateral oophorectomy or hysterectomy (for the Zostavax® sub-study only). * Female participants of childbearing potential may be enrolled in the study if the participant (for the Shingrix® sub-study only): * Has practiced adequate contraception for 30 days prior to vaccination; and * Has a negative urine pregnancy test on the day of the first vaccination; and * Has agreed to continue adequate contraception during the primary treatment period and for 2 months after completion of the vaccination series (Week 16) * Patients must have a history of prior chicken pox (for the Zostavax® sub-study only; for patients who do not recall prior chicken pox, a positive varicella IgG serology can be used to document prior exposure) Exclusion criteria include: * prior Zostavax® receipt (for the Zostavax® sub-study only; the Shingrix® sub-study will allow prior Zostavax® receipt if 6 months or greater prior to enrollment) * active contraindications to vaccination including allergy or sensitivity to gelatin or any other vaccine component * acute illness or infection * HIV/AIDS * current systemic corticosteroid use (including any oral or parenteral…